The specific aim of this grant is to mentor young clinical investigators, primarily in the area of research related to the control of symptoms caused by cancer and/or cancer therapy. A time comes in an investigator's career when a previously mentored person becomes the mentor. Although it might not be easy to admit, being more than half way through my career, I have made the transformation from primarily being mentored, to being a mentor. I am currently the Director of the Cancer Control Program of the North Central Cancer Treatment Group (NCCTG) as well as the co-director of the Cancer Prevention and Control Program of the Mayo Clinic Comprehensive Cancer Center. I have been the Principal Investigator of a community clinical oncology program (CCOP) research base grant for over a decade and have received R01 grant funding in the past. Through this effort, I have, arguably, developed the most productive program in the world designed to evaluate means of alleviating symptoms caused by cancer and/or cancer therapy. Using this background, with the funds obtained from this grant I will provide mentorship for young clinical investigators interested in a career in clinical research related to relief of symptoms from cancer and/or cancer therapy. I will use an """"""""on-the-job"""""""" training approach to help them with the development of applicable protocols. I will mentor them through the protocol review process, through the conduct of clinical trials, and through the process to report results as scientific abstracts and manuscripts. I will facilitate their leadership of subsections of the Mayo Oncology Symptom Control Program. I will facilitate their development of independent grant funding. I view this as a process of succession planning, expecting that one or more of these mentored individuals will eventually take my place and continue to promulgate the symptom control research program that we have at Mayo Clinic, allowing them to mentor the next generation of investigators. This role as a mentor allows me to give back to the scientific field some of the fruits from the mentoring that was provided to me in my early career. This should allow for continued investigation for promising means for alleviating symptoms related to cancer and/or cancer therapy. This will improve the care of patients with cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Scientist Award (K05)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Miller, Robert C; Petereit, Daniel G; Sloan, Jeff A et al. (2016) N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys 95:1168-74
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Pachman, Deirdre R; Weisbrod, Breanna L; Seisler, Drew K et al. (2015) Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer 23:943-51
Kadakia, Kunal C; Leal, Alexis D; Seisler, Drew K et al. (2014) Antiemetic prescribing practices using a computerized physician order entry system. Support Care Cancer 22:217-23
Kadakia, Kunal C; Rozell, Shaina A; Butala, Anish A et al. (2014) Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage 47:1100-15
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Leal, A D; Kadakia, K C; Looker, S et al. (2014) Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer 22:1313-7
Staff, Nathan P; Podratz, Jewel L; Grassner, Lukas et al. (2013) Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 39:124-31
Stan, Daniela; Loprinzi, Charles L; Ruddy, Kathryn J (2013) Breast cancer survivorship issues. Hematol Oncol Clin North Am 27:805-27, ix

Showing the most recent 10 out of 46 publications